Status:
ACTIVE_NOT_RECRUITING
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Hematologic Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes. We hypothesize that identification of a graft...
Detailed Description
This is a clinical trial for subjects with hematologic malignancies ( acute leukemia, myeloproliferative disorders, lymphoma, myeloma) who are in need of a donor stem cell transplant, and for whom an ...
Eligibility Criteria
Inclusion
- Subject must have a confirmed diagnosis of:
- Previously Relapsed or refractory acute leukemia (myeloid or lymphoid)
- Acute leukemia in first remission at high-risk for recurrence
- Chronic myelogenous leukemia in chronic, accelerated phase or blast-crisis
- Recurrent or refractory malignant lymphoma or Hodgkin lymphoma
- Chronic lymphocytic leukemia, relapsed or with poor prognostic features
- Multiple myeloma
- Myelodysplastic syndrome
- Chronic myeloproliferative disease
- Hemoglobinopathies
- Aplastic anemia
- Other hematological disorder in need of allogeneic transplant (e.g. blastoid dendritic cell neoplasm)
- Age ≥ 18 years
- Likely to benefit from allogeneic transplant in the opinion of the transplant physician
- An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame.
- Karnofsky (KPS) Performance status of \>= 70%
- Acceptable organ function as defined below: Serum bilirubin: \< 2.0mg/dL ALT(SGPT): \< 3 X upper limit of normal Creatinine Clearance: \> 50 mL/min/1.73m2 (as estimated by the modified MDRD equation)
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Life expectancy is severely limited by concomitant illness or uncontrolled infection
- Severely decreased Left Ventricular Ejection Fraction (LVEF) or impaired pulmonary function tests (PFT's)
- Evidence of chronic active hepatitis or cirrhosis
- Uncontrolled HIV disease
- Pregnant or lactating
Key Trial Info
Start Date :
October 16 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2028
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT01810588
Start Date
October 16 2012
End Date
April 1 2028
Last Update
September 2 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
2
Weill Cornell Medical College
New York, New York, United States, 10065